Biocon Biologics biosimilar available in US, to treat inflammatory diseases

Posted on by

Biocon Biologics, a subsidiary of Biocon, said Monday that its biosimilars for treating certain inflammatory diseases are now available on the US market.

HULIO (adalimumab) injection, a biosimilar alternative to Humira (adalimumab), is now available to patients in the United States after five years of experience in Europe and two years in Canada, the company said.

“The launch of HULIO, our biosimilar adalimumab, in the US, is an important milestone for Biocon Biologics as it expands the offering of our well-known biosimilar product to patients in the US,” Biocon Biologics CEO and Managing Director Shreehas Tambe said in a statement.

He added that this launch comes as a result of the company’s strong presence in the field of oncology and diabetes.

(Only the title and image for this report may have been reworked by the Business Standard staff; the rest of the content is generated automatically from a shared feed.)

First published: Jul 03 2023 | 11:09 PM ist